CRISPR Improves ex vivo Donor Organ Treatment
Researchers are exploring the use of CRISPR-based RNA silencing during ex vivo machine perfusion to improve the quality of donor organs before transplantation. This approach aims to reduce injury-response pathways and viral loads without permanently altering the donor's genome.
Why it matters
Improving the viability of donor organs could significantly reduce organ shortages and improve transplant success rates.
A perspective article in Nature Reviews Bioengineering outlines how CRISPR-based RNA silencing could be integrated into ex vivo machine perfusion of donor organs before transplantation. Drawing on early proof-of-concept work, the authors argue that transient gene silencing could improve organ quality and reduce pathogen burden without directly editing patients.
The article is a technical summary of scientific research published in a peer-reviewed journal context.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in